TD Cowen Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $61.00

Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its price objective increased by TD Cowen from $59.00 to $61.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on RARE. Wedbush reissued a neutral rating […]

Related Keywords

United States ,Japan ,Canada ,America ,Robertw Baird ,Dekabank Deutsche Girozentrale ,Thomas Richard Kassberg ,Charles Schwab Investment Management Inc ,Jpmorgan Chase Co ,Cantor Fitzgerald ,Royal Bank ,Deutsche Bank ,Securities Exchange Commission ,Vanguard Group Inc ,Ultragenyx Pharmaceutical Inc ,Ultragenyx Pharmaceutical ,Free Report ,Moderate Buy ,Get Free Report ,Richard Kassberg ,Exchange Commission ,John Richard Pinion ,Schwab Investment Management ,Bank Deutsche Girozentrale ,Pharmaceutical Inc ,North America ,Latin America ,Ultragenyx Pharmaceutical Daily ,Nasdaq Rare ,Rare ,Medical ,Boost Price Target ,Td Cowen ,